Cross-Party Group on Life Sciences Discusses Ozempic

I chaired a fascinating Cross-Party Group on Life Sciences meeting at the Scottish Parliament last week.

Professor Naveed Sattar gave an enlightening talk on the broader implications of GLP-1 receptor agonists, like Ozempic, now licensed as weight management medicines, and their impact on healthcare systems and public health strategy.

These drugs can help reduce diabetes, stroke, and heart problems. However, they are expensive.

It’s important that those who can obtain the most benefit, do so.

Gerard Cunningham, a Global Scot and serial entrepreneur, shared his vision on transforming Scotland’s life sciences startups into billion-dollar enterprises.

There was also a ministerial update and Q&A session from Minister for Business Richard Lochhead MSP.

Thank you to all those who attended and the team at the Association of the British Pharmaceutical Society Scotland.